SCHEMBL13059409

SCHEMBL13059409

CCCC(=O)N1CC[C@@H](F)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.50
CHRNA3 P32297 1/20 0.50
CHRNA4 P43681 1/20 0.50
CHRNB3 Q05901 1/20 0.50
CHRNA6 Q15825 1/20 0.50
DPP4 P27487 5/20 0.49
DPP8 Q6V1X1 1/20 0.49
DPP9 Q86TI2 1/20 0.49
GNAI3 P08754 6/20 0.47
GNAO1 P09471 6/20 0.47
GNAI1 P63096 6/20 0.47
MEN1 O00255 1/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
NPC1 O15118 1/20 0.44
EPHX2 P34913 3/20 0.41
EPHX1 P07099 2/20 0.41
PDE4B Q07343 1/20 0.40
DPP7 Q9UHL4 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12945382 1.00 CHRNB2 (0.50) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL13059514 0.88 GNAI3 (0.54) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL9946443 0.86 CHRNB2 (0.60) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL10305046 0.84 DPP4 (0.51) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL10305033 0.84 DPP4 (0.51) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL14996176 0.84 DPP4 (0.51) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL13459961 0.83 GNAI3 (0.58) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL14275539 0.83 GNAI3 (0.58) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL10274495 0.81 MEN1 (0.65) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL9221110 0.81 CHRNB2 (0.50) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020249792-A1 SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-12-17 WO disclosed
US-20180099974-A1 METHODS OF TREATING OR PREVENTING A PROTEOPATHY USHER III INITIATIVE, INC. 2018-04-12 US disclosed
US-20100311732-A1 NOVEL HETEROCYCLIC COMPOUNDS PANACEA BIOTEC PHARMA LIMITED (IN) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099974-A1 METHODS OF TREATING OR PREVENTING A PROTEOPATHY PSMG3, HSPA5, TTR CHRNB2 3153/4885CHRNA3 3432/4885CHRNA4 3722/4885
US-20100311732-A1 NOVEL HETEROCYCLIC COMPOUNDS DPP4, DPP3, DPP8 CHRNB2 4621/4885CHRNA3 3730/4885CHRNA4 3032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.